Patients with drug-resistant tuberculosis face potentially fatal delays in receiving treatment because there is little incentive for pharmaceutical companies to register second-line therapies in Australia, experts say.

Doctors can import and prescribe unregistered drugs but must file an application to the TGA’s Special Access Scheme for each patient.